Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML
Public ClinicalTrials.gov record NCT00780598. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
The OPAL Study: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in Elderly Subjects With Treatment Refractory or Relapsed Acute Myeloid Leukemia
Study identification
- NCT ID
- NCT00780598
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Chroma Therapeutics
- Industry
- Enrollment
- 76 participants
Conditions and interventions
Conditions
Interventions
- Tosedostat Drug
Drug
Eligibility (public fields only)
- Age range
- 60 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2009
- Primary completion
- Feb 28, 2011
- Completion
- Feb 28, 2011
- Last update posted
- Jun 27, 2012
2009 – 2011
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA School of Medicine | Los Angeles | California | 90095 | — |
| Washington Cancer Institute | Washington D.C. | District of Columbia | 20010 | — |
| M.D. Anderson Cancer Center Orlando | Orlando | Florida | 32806 | — |
| Emory University Clinic | Atlanta | Georgia | 30322 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| University of Michigan Health System | Ann Arbor | Michigan | 48109-0008 | — |
| Washington University, Oncology/Bone Marrow Transplant | St Louis | Missouri | 63110 | — |
| John Theurer Cancer Center, Hackensack University Medical Center, | Hackensack | New Jersey | 07601 | — |
| Monter Cancer Center | Lake Success | New York | 11042 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10065 | — |
| Weill Cornell Medical College - New York Presbyterian Hospital | New York | New York | 10065 | — |
| Stony Brook University Medical Center | Stony Brook | New York | 11794-7007 | — |
| Montefiore Medical Center Weiler Division | The Bronx | New York | 10461 | — |
| Duke Univeristy Medical Center | Durham | North Carolina | 27710 | — |
| Taussig Cancer Institute | Cleveland | Ohio | 44195 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Froedtert Hospital | Milwaukee | Wisconsin | 53226-3596 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00780598, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 27, 2012 · Synced May 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00780598 live on ClinicalTrials.gov.